Immunotherapy / PD-1 inhibitorPhase 3 trialInvestigational
Avelumab
How it works
Blocks a protein that helps cancer cells evade the immune system, allowing the immune system to attack and destroy the cancer cells.
Cancer types
Efficacy
In clinical trials, avelumab improved overall response rate in patients with ovarian cancer, with a response rate of approximately 21%.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| New Combination Treatment Shows Promise for Rare Neuroendocrine Tumors | Pancreatic Cancer | phase-2 | The 6-month objective response rate was 18% (95% confidence interval: 8-31%), with a median progression-free survival of 5.5 months (95% CI: 3.6-8). | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.